After a two year campaign, those with LGMD will now have a diagnostic code that matches their diagnosis! C3 is proud to have played a role in this victory alongside our friends and advocacy partners, including the Muscular Dystrophy Association,
C3 funds development of new LGMD2A/R1 disease model for preclinical testing
Coalition to Cure Calpain 3 (C3) is pleased to announce the funding of a new research award to Dr. Pia Elustondo of AGADA Biosciences. This project will characterize a novel LGMD2A/R1 disease model and utilize this model to test several
C3 awards grant to University of Florida researchers to investigate calcium handling in LGMD2A/R1
Coalition to Cure Calpain 3 (C3) is driving LGMD2A/R1 research by awarding a new grant to Dr. Elisabeth Barton and Dr. Lan Wei-LaPierre of the University of Florida. The project is titled “Strategies to improve calcium handling in LGMD2A/R1.” LGMD2A/R1
LGMD diagnostic codes proposed for final implementation
BIG NEWS! New diagnostic codes for those living with LGMD that match their diagnosis are likely on their way! Coalition to Cure Calpain 3 has been working with Muscular Dystrophy Association and other LGMD foundations, patients, and expert physicians to
Do you have questions about LGMD2A/R1?
Coalition to Cure Calpain 3 has answers! Click here to read our recently updated Frequently Asked Questions (FAQs) for patients and families.
Sarepta Therapeutics Q1 Update on LGMD Programs
Sarepta Therapeutics recently published a Community Letter to share updates on their limb-girdle muscular dystrophy gene therapy programs. Click here to access the letter on Sarepta’s website.
Daniel Ferguson LGMD Foundation Launches
C3 is pleased to share the launch of an Australian-based organization, the Daniel Ferguson LGMD Foundation. This registered charity aims to improve the lives of those living with LGMD2A/R1 by improving awareness, increasing genetic testing, and enabling those living with
Join Coalition to Cure Calpain 3 in celebrating Rare Disease Day!
Rare Disease Day takes place on the last day of February every year, with the goal of raising awareness about rare diseases and their impact on patients’ lives. Over 300 million people are living with one or more of over
Have you participated in a clinical research study?
Attention Individuals with LGMD2A/R1: Coalition to Cure Calpain 3 wants to hear from you! If you have participated in clinical research, such as a natural history study, an observational study, or a clinical trial, please follow this link to answer
What’s on the Horizon for LGMD2A/R1?
Dr. Jennifer Levy, Coalition to Cure Calpain 3 Scientific Director, is a proud contributor to the Winter 2022 issue of LGMD News. This magazine, a project of The Speak Foundation, publishes up-to-date information for the LGMD community. Dr. Levy’s article